The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
Groverlad - good to see you back mate. Always a good sign, the harder you try to bring the SP down, the higher it climbs.
Although most people consider you to be like a genital wart, I view you as a four leaf clover. Hang in there kid. Xx
“The Company believes the TYK2/JAK1 signalling pathway which it is pursuing offers potential for superior efficacy compared with agents, such as deucravacitinib, which block just one of the two kinases.”
Tim sounding very bullish.
SCH……sadly I don’t think it will help.
It must be hard work being negative about every investment one has……. Makes you feel blue.
More interesting, in my opinion is the fact the self proclaimed Professor of the English Language, who loves nothing more than correcting other posters grammatical errors. Has actually incorrectly spelt his own user name….. sorry to be so negative.
Good afternoon HBD.
A global patent or the facility to file for a global patent does not exist. When filing for a patent, for example in the U.K. you have a window of 18months from the date of the original filing (priority date) to start the process in another country or country’s. A separate application has to be made for each separate territory. And there is no automatic guarantee that it will be granted despite it being granted in the original country. The patent cooperation treaty (PCT), which the majority of countries are signed up to, aims to streamline the process.
In a nutshell a U.K. patent prevents the selling, manufacturing of the protected product/ process in the U.K. but doesn’t stop infringement in any other country.
SCHeckler, it’s an interesting statement. Particularly as they make a point about not having any influence or direct line of comm’s with GSK ref the SRA737 deal. In fact they claim they are speaking regularly with CRT ref STA737.
Yet the statement could easily lead one to the inference that they are party to confidential information that’s not yet in the public domain. Can only assume this has come from CRT??? Who knows.
“We can't divulge anything Gsk haven't put into the public domain”
Groverlad. I assume would agree BP is a pretty solid company? It’s share price is very similar to where it was 5 years ago, and it makes significant profits. Now have a look at the percentage increase in Sareum SP from where it was 5 years ago.
Yes, I would imagine there are a lot of people frustrated at reading the complete toilet deposits yo post. All my own opinion, please do your own research all alternative trash other people research with constant negativity and nothing else.
C79, thanks for the info. Looking at the co-inventors (Julian Northern) it would appear very likely that Onyx scientific are the people manufacturing the capsules for the trials.
"Our Phase I-III small molecule API development and manufacturing services support you through each preclinical research stage. Led by a team of highly skilled chemists, our approach focuses on seamlessly moving APIs from the lab to the plant, offering a smooth and flexible process from quality assurance and GMP manufacture through to analytical method development and stability testing".
https://onyxipca.com/cmc-services/?_gl=1*1yu6wsg*_up*MQ..&gclid=EAIaIQobChMI-aeBr8K--QIVwoFQBh2qOgWEEAAYASAAEgLJF_D_BwE#section-3
Colbaltblue, do you think its a negative that GSK now own SRA 737? do you not feel it has a far better chance of being progressed now that its in the hands of a major? curious to hear how you feel as an investor
Good afternoon SOG,
This is an interested read, published last month.
"Analyses of clinical trial data from 2010 to 2017 show four possible reasons attributed to the 90% clinical failures of drug development: lack of clinical efficacy (40%–50%), unmanageable toxicity (30%), poor drug-like properties (10%–15%), and lack of commercial needs and poor strategic planning (10%)"
https://www.sciencedirect.com/science/article/pii/S2211383522000521#:~:text=Analyses%20of%20clinical%20trial%20data,(10%25)2%2C4.
Regards
Okay Colbaltblue, I appreciate positivity is not your thing. However please take a look at this recent study the author is Shingo Yamaguchi an employee of GlaxoSmithKline K.K., Tokyo, Japan.
Approval success rates of drug candidates based on target, action, modality, application, and their combinations.
"The current success rate of a drug candidate, from the beginning of the clinical trial to receiving marketing approval, is about 10%-20%, and it has not changed during the past few decades."
Moreover, after analyzing the combinations of these parameters, the approval success rates of drugs that corresponded to the following categories-a stimulant in drug action or an enzyme in drug target and biologics in drug modality-were high (34.1% and 31.3%, respectively)
My understanding is SDC-1801 is the later of the two categories.
https://pubmed.ncbi.nlm.nih.gov/33831276/
This might be a decent read for those who are questioning the time things take and the costs involved. Hopefully it will highlight what little old Sareum has actually achieved so far.
"Developing a new drug from original idea to the launch of a finished product is a complex process which can take 12–15 years and cost in excess of $1 billion."
Target Identification:
"Drugs fail in the clinic for two main reasons; the first is that they do not work and the second is that they are not safe. As such, one of the most important steps in developing a new drug is target identification and validation."
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3058157/
Warty: It’s pretty clear in your own post “ the CRT Pioneer Fund, has today licensed exclusive and worldwide rights for the Chk1 inhibitor ”
Who does it say has licensed the inhibitor??????
It’s an agreement and there are only 2 legally bound parties. SAR have a financial benefit under the licence but they are not part of the agreement. They are a third party and it isn’t that unusually in the IP world. A patent holder may license a product to another party who then may enter into a distribution agreement with a corporate group. Same situation.